Difference between revisions of "STBT5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(6 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | ||
+ | __TOC__ | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big> | |+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big> | ||
Line 16: | Line 17: | ||
!'''Date of Last Editor Review''' | !'''Date of Last Editor Review''' | ||
!'''Notes''' | !'''Notes''' | ||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |||
| | | | ||
− | + | ==== CHAPTER 2 (SOFT TISSUE TUMOURS) ==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
---- | ---- | ||
Line 54: | Line 41: | ||
|[[STBT5:Lipoma|Lipoma]] | |[[STBT5:Lipoma|Lipoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 70: | Line 52: | ||
|[[STBT5:Lipomatosis|Lipomatosis]] | |[[STBT5:Lipomatosis|Lipomatosis]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 86: | Line 63: | ||
|[[STBT5:Lipomatosis_of_nerve|Lipomatosis of nerve]] | |[[STBT5:Lipomatosis_of_nerve|Lipomatosis of nerve]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 102: | Line 74: | ||
|[[STBT5:Lipoblastoma_and_lipoblastomatosis|Lipoblastoma and lipoblastomatosis]] | |[[STBT5:Lipoblastoma_and_lipoblastomatosis|Lipoblastoma and lipoblastomatosis]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 123: | Line 90: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Myolipoma_of_soft_tissue|Myolipoma of soft tissue]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 132: | Line 105: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Chondroid_lipoma|Chondroid lipoma]] |
|Disease | |Disease | ||
| | | | ||
Line 142: | Line 115: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Spindle_cell_lipoma_and_pleomorphic_lipoma|Spindle cell lipoma and pleomorphic lipoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 155: | Line 126: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Hibernoma|Hibernoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 164: | Line 138: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Atypical_spindle_cell_/_pleomorphic_lipomatous_tumour|Atypical spindle cell / pleomorphic lipomatous tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 174: | Line 148: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 187: | Line 159: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dedifferentiated_liposarcoma|Dedifferentiated liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 196: | Line 171: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 206: | Line 181: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Pleomorphic_liposarcoma_|Pleomorphic liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 219: | Line 192: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myxoid_pleomorphic_liposarcoma|Myxoid pleomorphic liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 228: | Line 204: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Nodular_fasciitis|Nodular fasciitis]] |
|Disease | |Disease | ||
| | | | ||
Line 238: | Line 214: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Proliferative_fasciitis_and_proliferative_myositis|Proliferative fasciitis and proliferative myositis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 251: | Line 225: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 260: | Line 237: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Ischaemic_fasciitis|Ischaemic fasciitis]] |
|Disease | |Disease | ||
| | | | ||
Line 270: | Line 247: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Elastofibroma|Elastofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 275: | Line 255: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 288: | Line 268: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Fibromatosis_colli|Fibromatosis colli]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 299: | Line 280: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 308: | Line 292: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Inclusion_body_fibromatosis|Inclusion body fibromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 318: | Line 302: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 331: | Line 313: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_fibroblastoma|Desmoplastic fibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 340: | Line 325: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Myofibroblastoma|Myofibroblastoma]] |
|Disease | |Disease | ||
| | | | ||
Line 350: | Line 335: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Calcifying_aponeurotic_fibroma|Calcifying aponeurotic fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 363: | Line 346: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:EWSR1-SMAD3-positive_fibroblastic_tumour_(emerging)|EWSR1-SMAD3-positive fibroblastic tumour (emerging)]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 372: | Line 358: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Angiomyofibroblastoma|Angiomyofibroblastoma]] |
|Disease | |Disease | ||
| | | | ||
Line 382: | Line 368: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 395: | Line 379: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiofibroma_of_soft_tissue|Angiofibroma of soft tissue]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 404: | Line 391: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Nuchal-type_fibroma|Nuchal-type fibroma]] |
|Disease | |Disease | ||
| | | | ||
Line 414: | Line 401: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 427: | Line 412: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Gardner_fibroma|Gardner fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 436: | Line 424: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 443: | Line 431: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 452: | Line 446: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Lipofibromatosis|Lipofibromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 462: | Line 456: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Giant_cell_fibroblastoma|Giant cell fibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 475: | Line 467: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 484: | Line 479: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
|Disease | |Disease | ||
+ | |Shashi Shetty and Reba Daniel (resident) | ||
+ | |2/21/2024 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
− | | | + | |Template added 2/21/2024 |
− | | | + | |- |
+ | |[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 500: | Line 501: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Low-grade_myofibroblastic_sarcoma|Low-grade myofibroblastic sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 510: | Line 511: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 523: | Line 522: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 532: | Line 534: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 542: | Line 544: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Adult_fibrosarcoma|Adult fibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 555: | Line 555: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myxofibrosarcoma|Myxofibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 564: | Line 567: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Low-grade_fibromyxoid_sarcoma|Low-grade fibromyxoid sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 574: | Line 577: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Sclerosing_epithelioid_fibrosarcoma|Sclerosing epithelioid fibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 579: | Line 585: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 592: | Line 598: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Deep_fibrous_histiocytoma|Deep fibrous histiocytoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 603: | Line 610: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Plexiform_fibrohistiocytic_tumour|Plexiform fibrohistiocytic tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 612: | Line 622: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]] |
|Disease | |Disease | ||
| | | | ||
Line 622: | Line 632: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Synovial_haemangioma|Synovial haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 635: | Line 643: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Intramuscular_angioma|Intramuscular angioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 644: | Line 655: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]] |
|Disease | |Disease | ||
| | | | ||
Line 654: | Line 665: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Venous_haemangioma|Venous haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 659: | Line 673: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 673: | Line 687: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Epithelioid_haemangioma|Epithelioid haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 683: | Line 697: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 692: | Line 710: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Tufted_angioma_and_kaposiform_haemangioendothelioma|Tufted angioma and kaposiform haemangioendothelioma]] |
|Disease | |Disease | ||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
| | | | ||
Line 708: | Line 721: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Retiform_haemangioendothelioma|Retiform haemangioendothelioma]] |
|Disease | |Disease | ||
| | | | ||
Line 718: | Line 731: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 731: | Line 742: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 740: | Line 754: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Kaposi_sarcoma|Kaposi sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 747: | Line 761: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Pseudomyogenic_haemangioendothelioma|Pseudomyogenic haemangioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 756: | Line 776: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Epithelioid_haemangioendothelioma|Epithelioid haemangioendothelioma]] |
|Disease | |Disease | ||
| | | | ||
Line 766: | Line 786: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiosarcoma|Angiosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 779: | Line 797: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Glomus_tumour|Glomus tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 788: | Line 809: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]] |
|Disease | |Disease | ||
| | | | ||
Line 798: | Line 819: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angioleiomyoma|Angioleiomyoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 811: | Line 830: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Leiomyoma|Leiomyoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 820: | Line 842: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:EBV-associated_smooth_muscle_tumour|EBV-associated smooth muscle tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 830: | Line 852: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 843: | Line 863: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Leiomyosarcoma|Leiomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 852: | Line 875: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Rhabdomyoma|Rhabdomyoma]] |
|Disease | |Disease | ||
| | | | ||
Line 862: | Line 885: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Embryonal_rhabdomyosarcoma|Embryonal rhabdomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 875: | Line 896: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Alveolar_rhabdomyosarcoma|Alveolar rhabdomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 884: | Line 908: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Pleomorphic_rhabdomyosarcoma|Pleomorphic rhabdomyosarcoma]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 900: | Line 919: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 910: | Line 929: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Ectomesenchymoma|Ectomesenchymoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 923: | Line 940: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 932: | Line 952: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Soft_tissue_chondroma|Soft tissue chondroma]] |
|Disease | |Disease | ||
| | | | ||
Line 942: | Line 962: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Extraskeletal_osteosarcoma|Extraskeletal osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 955: | Line 973: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Schwannoma|Schwannoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 964: | Line 985: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Neurofibroma|Neurofibroma]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 980: | Line 996: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Perineurioma|Perineurioma]] |
|Disease | |Disease | ||
| | | | ||
Line 990: | Line 1,006: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Granular_cell_tumour|Granular cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,003: | Line 1,017: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dermal_nerve_sheath_myxoma|Dermal nerve sheath myxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,012: | Line 1,029: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,022: | Line 1,039: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,035: | Line 1,050: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,044: | Line 1,062: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Hybrid_nerve_sheath_tumour|Hybrid nerve sheath tumour]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,060: | Line 1,073: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,070: | Line 1,083: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,083: | Line 1,094: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Intramuscular_myxoma|Intramuscular myxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,092: | Line 1,106: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Juxta-articular_myxoma|Juxta-articular myxoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,102: | Line 1,116: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,115: | Line 1,127: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Atypical_fibroxanthoma|Atypical fibroxanthoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,124: | Line 1,139: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,140: | Line 1,150: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Ossifying_fibromyxoid_tumour|Ossifying fibromyxoid tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,147: | Line 1,157: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Myoepithelioma,_myoepithelial_carcinoma,_and_mixed_tumour|Myoepithelioma, myoepithelial carcinoma, and mixed tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,156: | Line 1,172: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]] |
|Disease | |Disease | ||
| | | | ||
Line 1,166: | Line 1,182: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,179: | Line 1,193: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Phosphaturic_mesenchymal_tumour|Phosphaturic mesenchymal tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,188: | Line 1,205: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:NTRK-rearranged_spindle_cell_neoplasm_(emerging)|NTRK-rearranged spindle cell neoplasm (emerging)]] |
|Disease | |Disease | ||
+ | |James Solomon, MD, PhD | ||
+ | |2/20/2022 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Alanna Church | ||
| | | | ||
| | | | ||
− | | | + | |- |
+ | |[[STBT5:Synovial_sarcoma|Synovial sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,204: | Line 1,227: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Epithelioid_sarcoma|Epithelioid sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,214: | Line 1,237: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,227: | Line 1,248: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Clear_cell_sarcoma_of_soft_tissue|Clear cell sarcoma of soft tissue]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,236: | Line 1,260: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,243: | Line 1,267: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,252: | Line 1,282: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Extrarenal_rhabdoid_tumour|Extrarenal rhabdoid tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,262: | Line 1,292: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:PEComa|PEComa]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,275: | Line 1,303: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Intimal_sarcoma|Intimal sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,284: | Line 1,315: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Undifferentiated_sarcoma|Undifferentiated sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,294: | Line 1,325: | ||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ==== CHAPTER 3 (UNDIFFERENTIATED SMALL ROUND CELL SARCOMAS OF BONE AND SOFT TISSUE) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Ewing_sarcoma|Ewing sarcoma]] |
|Disease | |Disease | ||
+ | |Sadeem Qdaisat | ||
+ | |10/1/23 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Working with Eric McGinnis | ||
| | | | ||
− | | | + | |2021 template added |
− | | | + | |- |
+ | |[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,316: | Line 1,369: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
|Disease | |Disease | ||
+ | |Ganesh Pandurang, MD | ||
+ | |2/28/24 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
| | | | ||
− | | | + | |- |
+ | |[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,332: | Line 1,391: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 4 (BONE TUMOURS) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[STBT5:Subungual_exostosis|Subungual exostosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,355: | Line 1,422: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,364: | Line 1,434: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Periosteal_chondroma|Periosteal chondroma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,374: | Line 1,444: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Enchondroma|Enchondroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,379: | Line 1,452: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteochondroma|Osteochondroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,392: | Line 1,465: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Chondroblastoma|Chondroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,403: | Line 1,477: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Chondromyxoid_fibroma|Chondromyxoid fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,412: | Line 1,489: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Osteochondromyxoma|Osteochondromyxoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,422: | Line 1,499: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Synovial_chondromatosis|Synovial chondromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,435: | Line 1,510: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Central_atypical_cartilaginous_tumour_/_chondrosarcoma,_grade_1|Central atypical cartilaginous tumour / chondrosarcoma, grade 1]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,444: | Line 1,522: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Secondary_peripheral_atypical_cartilaginous_tumour_/_chondrosarcoma,_grade_1|Secondary peripheral atypical cartilaginous tumour / chondrosarcoma, grade 1]] |
|Disease | |Disease | ||
| | | | ||
Line 1,454: | Line 1,532: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,467: | Line 1,543: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Secondary_peripheral_chondrosarcoma,_grades_2_and_3|Secondary peripheral chondrosarcoma, grades 2 and 3]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,476: | Line 1,555: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Periosteal_chondrosarcoma|Periosteal chondrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,486: | Line 1,565: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Clear_cell_chondrosarcoma|Clear cell chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,499: | Line 1,576: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,508: | Line 1,588: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Dedifferentiated_chondrosarcoma_|Dedifferentiated chondrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,518: | Line 1,598: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteoma|Osteoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,531: | Line 1,609: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteoid_osteoma_|Osteoid osteoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,540: | Line 1,621: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Osteoblastoma_|Osteoblastoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,550: | Line 1,631: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Low-grade_central_osteosarcoma|Low-grade central osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,563: | Line 1,642: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteosarcoma|Osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,572: | Line 1,654: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Parosteal_osteosarcoma_|Parosteal osteosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,582: | Line 1,664: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Periosteal_osteosarcoma_|Periosteal osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,595: | Line 1,675: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:High-grade_surface_osteosarcoma|High-grade surface osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,604: | Line 1,687: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Secondary_osteosarcoma|Secondary osteosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,614: | Line 1,697: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_fibroma_of_bone|Desmoplastic fibroma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,619: | Line 1,705: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrosarcoma_of_bone|Fibrosarcoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,632: | Line 1,718: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Haemangioma_of_bone|Haemangioma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,643: | Line 1,730: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,652: | Line 1,742: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,662: | Line 1,752: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,675: | Line 1,763: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Aneurysmal_bone_cyst|Aneurysmal bone cyst]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,684: | Line 1,775: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,694: | Line 1,785: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Non-ossifying_fibroma|Non-ossifying fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,707: | Line 1,796: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Benign_notochordal_cell_tumour_|Benign notochordal cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,716: | Line 1,808: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Conventional_chordoma|Conventional chordoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,726: | Line 1,818: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dedifferentiated_chordoma|Dedifferentiated chordoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,739: | Line 1,829: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,748: | Line 1,841: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Chondromesenchymal_hamartoma_of_chest_wall|Chondromesenchymal hamartoma of chest wall]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
| | | | ||
Line 1,764: | Line 1,852: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]] |
|Disease | |Disease | ||
| | | | ||
Line 1,774: | Line 1,862: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,787: | Line 1,873: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Simple_bone_cyst|Simple bone cyst]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,796: | Line 1,885: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Fibrocartilaginous_mesenchymoma|Fibrocartilaginous mesenchymoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,806: | Line 1,895: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrous_dysplasia|Fibrous dysplasia]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,819: | Line 1,906: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,828: | Line 1,918: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,838: | Line 1,928: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,851: | Line 1,939: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Bone_metastases|Bone metastases]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,860: | Line 1,951: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,870: | Line 1,961: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,883: | Line 1,972: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,892: | Line 1,984: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,908: | Line 1,995: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] |
|Disease | |Disease | ||
| | | | ||
Line 1,918: | Line 2,005: | ||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ==== CHAPTER 5 (GENETIC TUMOUR SYNDROMES OF SOFT TISSUE AND BONE) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
− | + | ---- | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[STBT5:Enchondromatosis|Enchondromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 2,918: | Line 2,040: | ||
|[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | ||
− | | | ||
− | | | ||
− | | | ||
− | | | ||
|- | |- | ||
|[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]] | |[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 2,950: | Line 2,062: | ||
|[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]] | |[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 2,966: | Line 2,073: | ||
|[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | |[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | ||
− | | | ||
− | | | ||
− | | | ||
− | | | ||
|- | |- | ||
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]] | |[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 2,998: | Line 2,095: | ||
|[[STBT5:Werner_syndrome|Werner syndrome]] | |[[STBT5:Werner_syndrome|Werner syndrome]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | |
Latest revision as of 13:47, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.